1Gordon AN,Tonda M,Sun S,et al.Long-term survival advantange for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer[J].Gynecol Oncol,2004,95(1):1 -8.
2Chen LM,Karlan BY.Recurrent ovarian carcinoma:is there a place for surgery?[J].Semin Surg Oncol,2000,19 (1):62-68.
3Bristow HE,del Carmen MG,Pannu HK,et al.Clinically occult recurrent ovarian cancer:patient selection for secondary cytored Thiypen uctive surgery using combined PET/CT[J].Gynecol Oncol,2003,90(3):519 -528.
4Carcia AA,Blessing JA,Lenz HJ,et al.Phase Ⅱ clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy with exploratory TS,DPD,and TP correlates:a Gynecologic Oncology Group study[J].Gynecol Oncol,2005,96(3):810-817.
5Meshkova IE,Kostromina EV,Trouk EB.Diagnostic potential of ultrasound examination for tumor recurrence and metastasis[J].Vopr Onkol,2000,46(1):84-87.
7Chang WC,Hung YC,Kao CH,et al.Usefuless of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucise(FDG) to detect recurrent ovarian cancer base on asymptomatically elevated serum levels of tumor marker (CA125 antigen)[J].Neoplasma,2002,49 (5):329-333.
8Takekuma M,Maeda M,Ozawa T,et al.Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer[J].Int J Clin Oncol,2005,10(1007):177-181.
9Sironi S,Messa C,Mangili G,et al.Integrated FDG PET/CT in patient with persistent ovarian cancer:correlation with histologic findings[J].Radiology,2004,233 (2):433 -440.
10Harries M,Gore M.Part Ⅱ:chemotherapy for epithelial ovarian cancer-troatment of recurrent disease[J].Lancet Oncol,2002,3(9):537 -545.
二级参考文献25
1Oehler MK;Bicknell R.The promise of anti-angiogenic cancer therapy,2000(04).
2Shen GH;Ghazizadeh M;Kawanami O.Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma[J],2000(2).
3Wagner U;Schlebusch H;Kohler S.Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125[J],1997(1).
4Reinartz S;Boerner H;Koehler S.Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA 125 by determination of intercellular cytokines-a preliminary report[J],1999(1).
5Ozols RF.Future directions in the treatment of ovarian cancer[J],2002.
6Canevari S;Stoter G;Arienti F.Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody[J],1995.
7Brustmann H;Naude S.Vascular endothelial growth factor expression in serous ovarian carcinoma:relationship with high mitotic activity and high FIGO stage[J],2002.
8Sewell JM;Macleod KG;Ritchie A.Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa")[J],2002(86).
9HidalgoM;Siu LL;Nemunaitis J.Phase I and pharmacologic study of OSI-774,an epidermal growth factor receptor tyrosine kinase inhibitor,in patients with advanced solid malignancies[J],2001.
10Eisen T;Boshoff C;Mak I.Continuous low dose Thalidomide:a phase II study in advanced melanoma,renal cell,ovarian and breast cancer,2000.
